8-KEarnings & ResultsMaterial AgreementsRegulation FD+1

DEXCOM INC 8-K Report, Material Agreement (Nov 2, 2011)

Filed November 2, 2011For Securities:DXCM

Summary

DexCom, Inc. (DXCM) has filed an 8-K report detailing a significant strategic partnership with Roche Diagnostics Operations, Inc. This agreement, effective November 1, 2011, allows Roche to integrate DexCom's future continuous glucose monitoring (CGM) technology with Roche's Accu-Chek® insulin delivery system in the United States. The partnership is structured with upfront milestone payments and a royalty component, indicating strong potential for future revenue streams for DexCom. This collaboration positions DexCom to leverage its innovative CGM technology within a broader diabetes management ecosystem, specifically targeting integration with insulin pumps. Investors should note the potential for increased market penetration and revenue growth as this integrated system is developed and commercialized. The agreement also includes provisions for further commercialization discussions, suggesting a path towards substantial long-term revenue from per-unit sales.

Key Highlights

  • 1DexCom entered into a Research and Development Agreement with Roche Diagnostics Operations, Inc. on November 1, 2011.
  • 2Roche gains the right to integrate DexCom's future CGM technology with its Accu-Chek® insulin delivery system in the U.S.
  • 3DexCom is eligible to receive up to $3 million in milestone payments.
  • 4An additional $1 million is designated to offset DexCom's development expenses for the integrated system.
  • 5An initial milestone payment of $500,000 was paid upon execution of the agreement.
  • 6Future commercialization agreement will include a per-unit royalty payment of $100 for each integrated system sold.
  • 7The initial term of the agreement runs until December 31, 2014, with automatic one-year renewals.

Frequently Asked Questions

The agreement allows Roche Diagnostics to integrate DexCom's future continuous glucose monitoring (CGM) technology with Roche's next-generation Accu-Chek® insulin delivery system for commercialization in the United States. This aims to create an integrated diabetes management solution.

DexCom stands to benefit financially through milestone payments totaling up to $3 million, a $1 million contribution towards development expenses, and importantly, a royalty of $100 for each integrated system sold under a future commercialization agreement. An initial $500,000 milestone payment was received upon signing.

The initial term of the Research and Development Agreement commenced on November 1, 2011, and will expire on December 31, 2014. It has the potential to automatically renew for successive one-year periods unless either party provides advance notice not to renew.

While the agreement outlines potential revenue streams through milestone payments and per-unit royalties, it is contingent on the successful development and future commercialization of the integrated system. The agreement also specifies that further commercialization terms will be detailed in a separate Commercialization Agreement.